Tacrolimus Inhibits NF-κB Activation in Peripheral Human T Cells by Vafadari, R. (Ramin) et al.
Tacrolimus Inhibits NF-kB Activation in Peripheral
Human T Cells
Ramin Vafadari, Rens Kraaijeveld, Willem Weimar, Carla C. Baan*
Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
Abstract
The calcineurin inhibitor, tacrolimus (TAC), inhibits the protein phosphatase activity of calcineurin, leading to suppression of
the nuclear translocation of NFAT and inhibition of T cell activation. Apart from NFAT also the transcription factor NF-kB
plays a key functional role in T cell activation. Therefore, blockade of the NF-kB activation cascade by immunosuppressive
drugs prevents immune activation. Here we studied whether TAC blocks NF-kB activation in peripheral human T cells. After
anti-CD3/CD28-activation of T cells from healthy volunteers, NF-kB (p65) phosphorylation was measured by flow cytometry
in CD3+ T cells, CD4+ helper T cells and CD8+ cytotoxic T cells in the absence and presence of TAC 10 ng/mL, sotrastaurin
500 nM (positive control) and mycophenolic acid 10 mg/mL (negative control; n = 6). NF-kB transcriptional activity was
measured by ELISA and intracellular TNFa protein, a downstream target, was measured by flow cytometry to assess the
functional consequences of NF-kB blockade. Anti-CD3/28-activation induced NF-kB phosphorylation in CD3+ T cells, CD4+ T
cells and CD8+ T cells by 34% (mean), 38% and 30% resp. (p,0.01). Sotrastaurin inhibited NF-kB activation in the respective
T cell subsets by 93%, 95% and 86% (p,0.01 vs. no drug), while mycophenolic acid did not affect this activation pathway.
Surprisingly, TAC also inhibited NF-kB phosphorylation, by 55% (p,0.01) in CD3+ T cells, by 56% (p,0.01) in CD4+ T cells
and by 51% in CD8+ T cells (p,0.01). In addition, TAC suppressed NF-kB DNA binding capacity by 55% (p,0.05) in CD3+ T
cells and TNFa protein expression was inhibited in CD3+ T cells, CD4+ T cells and CD8+ T cells by 76%, 71% and 93% resp.
(p,0.01 vs. no drug), confirming impaired NF-kB signaling. This study shows the suppressive effect of TAC on NF-kB
signaling in peripheral human T cell subsets, measured at three specific positions in the NF-kB activation cascade.
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Introduction
Tacrolimus (TAC) is a commonly used drug in the immuno-
suppressive regimen following solid organ transplantation [1]. It is
highly effective in the prevention of graft rejection [2,3,4,5], an
immunological process where T cells are often involved [6]. In
these cells TAC binds to and inhibits calcineurin after forming a
complex with the immunophilin FKBP12 (FK506 binding protein)
[7]. Calcineurin is activated after engagement of the T cell
receptor (TCR) and co-stimulation (i.e. CD28-receptor stimula-
tion). Activation of these receptors leads to depletion of
endoplasmatic reticulum calcium-stores into the cytosolar cell
compartment and following calcium influx via CRAC (calcium
release activated calcium current) channels to slowly replenish the
calcium levels in the endoplasmic reticulum [8]. Activation of the
calcium-dependent calcineurin leads to dephosphorylation and
translocation of nuclear factor of activated T cells (NFAT) into the
nucleus. NFAT binds in conjunction with AP-1 to DNA binding
sites and initiates transcription of pro-inflammatory cytokines (e.g.
IL-2 and IFNc) [8].
Since its introduction over two decades ago, textbooks without
exception have attributed the immunosuppressive effect of TAC to
inhibition of the calcineurin/NFAT pathway. Interestingly some
studies have linked inhibition of the calcineurin pathway to
suppression of NF-kB signaling in the Jurkat T cell line [9,10,11].
The interaction between these two major activation pathways is
still under investigation [12] and suggests that TAC also suppresses
T cell activation via the NF-kB pathway. In resting T cells IkB
(inhibitor of kB) proteins keep NF-kB inactive by masking its
nuclear localization sequence. After TCR-engagement and co-
stimulation, the inhibitory IkB proteins are degraded by IKK (IkB
kinase) complexes via the 26S proteasome. This enables the release
of NF-kB hetero-dimers primarily consisting of NF-kB1 (p50) and
RelA (p65) to enter the nucleus and bind to the kB sites within
promoters and enhancers thereby initiating transcription of
adhesion molecules, chemokines, regulators of apoptosis and
pro-inflammatory cytokines, e.g. tumor necrosis factor (TNF) a
[13,14]. Hence, the NF-kB signaling pathway is in-dispensable in
T cell biology and plays an important role in their development,
activation and survival [15,16]. Consequently NF-kB is an
important mediator of rejection processes after solid organ
transplantation [17,18].
The current study is the first to report on the effect of TAC on
the NF-kB activation pathway by quantitative analysis of NF-kB
phosphorylation in human primary T cell subsets. In addition, the
effects of TAC on NF-kB DNA binding activity and NF-kB
dependent cytokine production were analyzed. The analysis was
conducted in anti-CD3/CD28 activated peripheral T cells and the
effects were compared to those of sotrastaurin which inhibits
protein kinase C (PKC), the enzyme that mediates NF-kB-
activation after TNFa receptor engagement and TCR activation
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[19,20]. The immunosuppressant mycophenolic acid (MPA) which
blocks de novo biosynthesis of purine nucleotides and lymphocyte
proliferation by suppressing the enzyme inosine monophosphate
dehydrogenase, was used as negative control [21].
Materials and Methods
Isolation and stimulation of human peripheral T cells
The study protocol was approved by the local ethics committee
of the Erasmus medical center and written informed consent was
obtained from healthy volunteers. They had no clinical signs of
viral or bacterial infections and did not take any medication in the
3 days up to blood withdrawal. Peripheral blood mononuclear
cells (PBMC) were isolated from freshly drawn, heparinized
normal human whole blood by density-gradient centrifugation
over Ficoll-paque (Amersham Pharmacia Biotech, Uppsala,
Sweden) and frozen at 2135uC in RPMI 1640-DM (Gibco
BRL, Scotland, UK) supplemented with 2 mM/L L-glutamine
(Gibco BRL), 100 IU/mL penicillin (Gibco BRL), 100 ug/mL
streptomycin (Gibco BRL), 10% pooled human serum (Blood
Bank, Rotterdam, the Netherlands) and 10% dimethylsulfoxide
(Merck, Schuchardt, Germany). Defrosted PBMC were washed
twice with RPMI 1640 (Gibco BRL, Scotland, UK), supplemented
with 100IU/mL penicillin (Gibco BRL) and 100 ug/mL strepto-
mycin (Gibco BRL). Purified T cells were isolated by negative
selection using MACS magnetic cell separation with a pan T cell
isolation kit II (Miltenyi Biotech, Auburn, CA) according to
manufacturer’s instructions. Negative selection was used to avoid
possible T cell activation by binding to beads. Purity of the isolated
T cells was determined by flow cytometry using a CD3-AmCyan
monoclonal antibody (mAb; BD Biosciences, San Jose, CA), on a
FACS Canto II flow cytometer (BD Biosciences) along with facs
Diva, version 6.0 software (BD Biosciences). For each experiment
the purity of the magnetically isolated CD3+ T cells was at least
98%. Cells were rested overnight in IMDM medium supplement-
ed with 0.5 nM b-mercaptopurin (Sigma-Aldrich, Steinheim,
Germany) and 10% heat inactivated fetal bovine serum (FBS)
(BioWhittaker, Verviers, Belgium).
Phosphospecific flow cytometry
MACS isolated T cells (106) were spiked for three hours at 37uC
with drugs at the following final concentrations: TAC 0, 5, 10 and
50 ng/mL (Astellas Pharma Inc., Tokyo, Japan), sotrastaurin 50,
100 and 500 nM (Novartis Pharmaceuticals, Basel, Switzerland)
and mycophenolic acid 10 mg/mL (Sigma-Aldrich). Cells were
activated for ten minutes with mouse anti-human CD3 (UCHT1
clone, BD Pharmingen, San Diego, CA) and mouse anti-human
CD28 (28.2 clone, BD Pharmingen) 1 mg each, according to
manufacturer’s instructions at 37uC. Before activation the anti-
human CD3 and CD28 were cross-linked on ice using a polyclonal
goat anti-mouse immunoglobulin (BD Pharmingen). After activa-
tion cells were fixed for 10 min with Lyse/fix buffer (BD
Biosciences). Fixed cells were permeabilized using a 70% aqueous
ethanol solution and immediately cooled at 220uC. The
permeabilized samples were stained in the dark with fluorochrome
conjugated mAb mixtures for 30 min at room temperature. To
measure the intracellular signaling pathway, we used a PE-
conjugated mAb which recognizes phosphorylation at serine 529
in the activation domain of human NF-kB p65 (BD Biosciences).
The p65-isoform is abundantly expressed in all mammal cells,
including T cells [22,23]. Simultaneously with intracellular
staining the following mAb’s were used for cell surface staining:
CD4-PB and CD8-PE-Cy7 (BD Biosciences). Samples were
analyzed on a FACS Canto II flow cytometer (BD Biosciences).
Ten thousand gated cell events were acquired from each tube and
FMO negative control tubes were included.
Intracellular cytokine production
MACS isolated T cells (0.5?106) were spiked for one hour with:
TAC 0, 10 ng/mL or sotrastaurin 500 nM. Samples were
activated with 12.5 mL human T-activator CD3/CD28 Dyna-
beads (Invitrogen Dynal AS, Oslo, Norway) for 24 hours at 37uC.
The CD3 antibody coated on the dynabeads is specific for the
CD3e-chain. Golgistop (BD Biosciences) was added during
stimulation, which was stopped with EDTA, final concentration
2 mM. Beads were removed using a magnet and cells were fixed
and lysed for 10 minutes with 4 mL FACS lysing solution (BD
Biosciences). After washing, PBMC were permeabilized for
10 minutes with FACS perm solution II (BD Biosciences). Cells
were stained and measured on the flow cytometer as described
above. The following mAbs were used: CD4-PB, CD8-PE-CY7,
anti-IL-2-APC (BD Biosciences) and PE conjugated anti-TNFa
(BD Pharmingen).
ELISA
Enzyme-Linked Immunosorbent Assay (ELISA) was used to
analyze the effect of TAC on NF-kB DNA binding activity.
MACS isolated T cells (3?106) were spiked with: TAC 0, 10,
50 ng/mL ng/mL or sotrastaurin 500 nM for 1 hour. Next
samples were activated for 40 minutes at 37uC with mouse anti-
human CD3 (1 mg; BD Pharmingen) and mouse anti-human
CD28 (1 mg; BD Pharmingen). Nuclear extracts were prepared
using a nuclear extraction kit (Cayman Chemical, Ann Arbor,
MN). NF-kB p65 DNA binding activity was determined by an
ELISA kit (Cayman Chemical), according to the manufacturer’s
instructions. A bicinchoninic acid (BCA; Pierce, Rockford, IL)
assay was used to determine the total protein concentration of
nuclear extracts, using acetylated Bovine serum albumin (Pro-
mega, Madison, WI, USA) as standard.
Analysis of data
Statistical analysis was performed using Graph Pad Prism 5.0
(Graph Pad Software Inc., La Jolla, CA, USA). For statistical




In the first set of experiments signaling activation was studied
via phoshorylation of NF-kB p65 at serine 529. The latter is only
phosphorylated when the inhibitory IkB protein is released from
the NF-kB dimer complex [24,25]. NF-kB activation was
measured by phosphospecific flow cytometry as the percentage
of cells in which NF-kB phosphorylation was induced compared to
the unstimulated sample. Figure 1A shows an example of the
analysis of an unstimulated sample and an anti-CD3/CD28
stimulated sample, both stained with the monoclonal NF-kB
antibody. Stimulation increased the percentage of phospho-NF-kB
expressing CD3+ T cells from 1,3% in unstimulated samples to
35.0% in stimulated samples (mean, n= 6; p,0.01; figure 1B). In
the CD4+ and CD8+ T cell subsets NF-kB phosphorylation was
induced from 1.2% to 38.8% and from 1.2% to 31.6%
respectively (p,0.01).
The influence of different TAC concentrations on NF-kB
phosphorylation was measured and the immunosuppressive drug
inhibited NF-kB phosphorylation in a dose dependent manner in
CD3+ T cells, CD4+ T cells and CD8+ T cells, as did the positive
Tacrolimus Inhibits NF-kB
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control sotrastaurin (figure 2). The negative control, mycophenolic
acid, at a clinically high concentration of 10 mg/mL, did not affect
NF-kB activation (p.0.05 compared to no drug; figure 3). TAC
10 ng/mL inhibited NF-kB phosphorylation by 55.0% in CD3+ T
cells, by 55.7% in CD4+ T cells and by 51.2% in CD8+ T cells
(p,0.01 for all T cell subsets, figure 3). The positive control,
sotrastaurin 500 nM, strongly inhibited phosphorylation, by
93.9% in CD3+ T cells, by 94.0% in CD4+ T cells and by
89.7% in CD8+ T cells (p,0.01 for all T cell subsets; figure 3).
TAC also inhibited NF-kB phosphorylation in regulatory
CD4+25+1272 T cells (Treg; supplemental figure S1). These
cells are essential for immune homeostasis by suppressing effector
T cell responses [26]. NF-kB p65 is associated with induction of
Foxp3 transcription [27,28] which marks thymic Treg generation
[29]. Further studies are necessary to validate whether the
reduction of Treg numbers by calcineurin inhibitors [30,31,32]
is NF-kB mediated.
NF-kB binding to target-genes
After activation, phosphorylated NF-kB binds to DNA
sequences called kB sites and regulates their transcription. Here
we studied the downstream targets of NF-kB phosphorylation by
measuring the effects of immunosuppressive drugs on the DNA
binding activity of NF-kB p65 to its target-genes in CD3+ T cells.
For each sample the nuclear extract of purified CD3+ T cells
(3.106) from healthy volunteers was prepared for analysis by
ELISA. Figure 4A shows the mean amount of nuclear extract
expressed in mg protein for each tested condition. This was similar
at each of the tested conditions. Regarding NF-kB DNA binding
activity, unstimulated samples had a mean absorbance of 1.0 and
stimulated samples without drug had a mean absorbance of 2.1
(p,0.01 compared to unstimulated samples) with all individual
measurements within the linear range of the assay: smaller than 3
at OD450nM. The positive control drug sotrastaurin at 500 nM
inhibited the anti-CD3/28 induced DNA binding capacity of NF-
kB in peripheral T cells by 84.4% (p,0.05 compared to no drug),
Figure 1. Facs analysis of NF-kB phosphorylation in T cells. The total CD3+ T cell population was acquired by MACS isolation of PBMC from
healthy volunteers. A) Example scatter dot plots of an unstimulated sample (above) and an anti-CD3/CD28 stimulated sample to illustrate the gating
strategy for analysis of percentages CD3+, CD4+ and CD8+ T cells which express phosphorylated NF-kB. Both samples were stained with a
monoclonal antibody against phosphorylated NF-kB p65. B) The average percentages of cells with elevated NF-kB phosphorylation in unstimulated
and stimulated samples without drug are depicted as mean 6 SEM of 6 independent experiments.
doi:10.1371/journal.pone.0060784.g001
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while TAC 10 ng/mL inhibited the DNA binding capacity by
54.5% and TAC 50 ng/mL by 74.3% (both p,0.05).
Intracellular cytokine production
Translocation of NF-kB into the nucleus and subsequent
binding of NF-kB to its target-genes results in the downstream
expression of inflammatory cytokines, chemokines and immune
receptors. To examine TAC-induced effects on the expression of
inflammatory cytokines, intracellular TNFa and IL-2 production
was measured in T cell subsets. TNFa is an NF-kB-dependent
cytokine, while IL-2 was measured as a positive control for the
inhibition of the NFAT-pathway by tacrolimus. Purified CD3+ T
cells were stimulated for 24 hours by the engagement of both
TCR and CD28. Examples of the flow cytometric dot plots for
unstimulated and stimulated samples are given in figure 5A and C.
Tacrolimus abrogated the IL-2 production in CD3+, CD4+ and
CD8+ T cells (p,0.01 compared to no drug, figure 5B).
For TNFa, the mean percentages of cytokine-producing T cell
subsets for six experiments are depicted in figure 5D. Anti-CD3-
CD28 stimulation induced TNFa production in 15.0% of CD3+ T
cells, 24.0% of CD4+ T cells and 5.1% of CD8+ T cells (mean;
p,0.01 unstimulated vs stimulated samples). TAC 10 ng/mL
inhibited this TNFa production in CD3+, CD4+ and CD8+ T
cells by 75.9%, 71.4% and 93.1% respectively (p,0.01 compared
to no drug; figure 5D). Sotrastaurin inhibited the NF-kB
dependent cytokine production in the T cell subsets by 88.5%,
85.7%; and 88.0% respectively (p,0.01 compared to no drug;
figure 5D).
Discussion
The transcription factor NF-kB plays an important role in T cell
development, activation and survival [15,16]. These cells are an
important contributor to alloreactivity in organ transplant patients
[6]. TAC suppresses T cell activation and an effect on NF-kB in T
cells is eminent in unraveling its precise immunosuppressive
working mechanism. Previous studies have shown that very high
TAC concentrations interfere with IkB degradation [33] and IkB
kinase activity in T cell lines [12,34], without answering whether
the pathway and NF-kB activation are affected in peripheral
human T cells at low drug doses as used after allograft
transplantation.
The current study for the first time describes the effect of
clinically relevant TAC concentrations on the NF-kB signaling
pathway in peripheral human T cells. We quantitatively analyzed
distinct steps in the intracellular activation cascade, i.e. phosphor-
ylation of the NF-kB molecule (figure 2) and the downstream NF-
Figure 2. NF-kB phosphorylation inhibited at different TAC-concentrations. MACS isolated CD3+ T cells from healthy volunteers were
stimulated by anti-CD3/CD28 in the presence of TAC 0, 5, 10, 50 ng/mL or sotrastaurin 50, 100 and 500 nM. Inhibition of NF-kB phosphorylation is
shown for CD3+ T cells (above), CD4+ T cells and CD8+ T cells (below; mean 6 SEM of 6 independent experiments).
doi:10.1371/journal.pone.0060784.g002
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kB DNA binding activity (figure 4). Both parameters showed the
inhibitory effect of TAC on NF-kB activation, including the
inhibition of NF-kB phosphorylation in CD4+ helper T cells and
CD8+ cytotoxic T cells. Further downstream in the activation
cascade, production of the NF-kB-dependent cytokine TNFa was
also suppressed by TAC in the T cell subsets (figure 5).
The traditional view on the working mechanism of TAC is that
it binds a specific intracellular immunophilin FKBP12, to inhibit
calcineurin phosphatase activity and subsequently the production
of pro-inflammatory cytokines. Our finding that TAC also
interferes with T cell activation via the NF-kB pathway can be
explained by at least two theories. First, TAC can influence the
NF-kB pathway via calcineurin [10,11,12,35]. Biswas et al. [35]
showed that calcineurin binds to and inactivates the cytoplasmic
IkB in a mouse myoblast cell line, leading to activation of the
transcription factor NF-kB and its nuclear translocation. A
different mechanism of calcineurin mediated NF-kB activation
was proposed by Palkowitsch et al. [12] who showed that
downstream of TCR-CD28 engagement calcineurin controls
dephosphorylation of BCL10 to facilitate formation of the
Carma1, BCL10, MALT1 (CBM) complex, a pivotal step in the
activation of IkB kinase. Via the CBM-complex, calcineurin
phosphorylates IkB, leading to its proteosomal degradation and
NF-kB activation [12,36].
PKC phosphorylates Carma1 and is therefore also essential for
the formation of the CBM complex [37]. TAC did not inhibit NF-
kB activation to the same extent as the PKC inhibitor sotrastaurin
(figure 3 and 4). This might be explained by partial TAC-induced
calcineurin inhibition: even at 100 mg/mL this agent suppresses
calcineurin activity by only 50 to 70% [38,39]. Nevertheless,
TAC-induced NF-kB suppression cannot be trivialized, since in T
cells calcineurin activation is a pre-requisite for maximum IKK
activity and in vivo IkB phosphorylation. Hence, both PKC and
calcineurin are required for effective NF-kB activation [34].
Partial inhibition by TAC suggests that the affected activation
pathways are not paralyzed and can still function in other essential
NF-kB-dependent cell types, which is beneficial for the immuno-
suppressant’s efficacy and safety profile [40].
The second theory to explain how TAC influences NF-KB
activation involves the MAPK (mitogen activated protein kinase)
signaling pathway. Even though the precise mechanism is still
under investigation, we and others have shown that TAC in vitro
and in vivo inhibits the p38 MAPK activation pathway in human T
cells [41,42]. This finding can also explain NF-kB suppression by
TAC as the transcription factor p38 MAPK regulates both the
nuclear recruitment of NF-kB and its transcriptional activity
[43,44,45,46]. The signaling pathways downstream of the TCR,
like the calcineurin-NFAT pathway, the PKC/NF-kB pathway
Figure 3. NF-kB phosphorylation inhibited by immunosuppressive drugs. The effect of the immunosuppressive drugs mycophenolic acid
10 mg/mL, TAC 10 ng/mL and sotrastaurin 500 nM on NF-kB p65 phosphorylation in peripheral T cells from healthy volunteers is depicted.
Mycophenolic acid did not influence NF-kB phosphorylation (p.0.05), while the positive control sotrastaurin inhibited phosphorylation in the CD3+,
CD4+ and CD8+ T cell subsets (p,0.01 compared to no drug). TAC 10 ng/mL also suppressed phosphorylation in the T cell subsets (p,0.01; mean6
SEM of 6 independent experiments).
doi:10.1371/journal.pone.0060784.g003
Tacrolimus Inhibits NF-kB
PLOS ONE | www.plosone.org 5 April 2013 | Volume 8 | Issue 4 | e60784
and the MAPK pathway are highly interlinked and therefore it is
apprehensible that TAC inhibits activation of these pathways. This
is for example illustrated by studies which showed that p38 MAPK
induces transcription and translation of NFAT mRNA in T cells
[47] and controls NFAT transcriptional activity [48,49].
Besides investigating the mechanism of action, the current study
gives a new lead in the search for biomarkers of TAC-treatment in
transplant patients. While there is a need to study intracellular
activation pathways until now mostly the calcineurin-NFAT
pathway has been utilized [50]. The results of our study may
also influence planned clinical studies to combine sotrastaurin and
TAC [51,52]. Combining two drugs may be useful as sotrastaurin
mainly inhibits the PKC/NF-kB pathway, while TAC has a strong
effect on the calcineurin/NFAT pathway and as it now seems also
inhibits, though to a certain extent, the NF- kB pathway.
Therefore, an additional immunosuppressive effect of sotrastaurin
might be expected for patients on tacrolimus maintenance
therapy.
In conclusion, our study shows the suppressive effect of TAC on
NF-kB signaling in peripheral human T cell subsets, measured at
Figure 4. TAC inhibits NF-kB DNA-binding capacity in human T cells. MACS isolated CD3+ T cells (3.106) from three healthy volunteers were
stimulated in the presence of TAC 0, 10, 50 ng/mL or sotrastaurin 500 nM. A) The amount of nuclear protein extracted from the cells was comparable
in the samples and at the different tested conditions. B) The DNA binding capacity of NF-kB in the nuclear fractions was inhibited by both TAC and
the positive control sotrastaurin. Each bar represents the anti-CD3/CD28-stimulated NF-kB DNA binding capacity minus that of the unstimulated
sample (mean 6 SEM of 3 independent experiments).
doi:10.1371/journal.pone.0060784.g004
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three specific positions in the NF-kB activation cascade. Hence,
TAC is more than just a calcineurin inhibitor and a more
balanced view on its immunosuppressive working mechanism is
required.
Supporting Information
Figure S1 TAC inhibits NF-kB phosphorylation in
regulatory CD4+25+127- T cells. CD3+ T cells were acquired
by MACS isolation of PBMC from healthy volunteers. A)
Example scatter dot plots to illustrate the gating strategy for
selection of CD4+CD25+127- regulatory T cells (Tregs) from the
total CD4+ T cell population. B) Example scatter dot plots to
illustrate the percentage of Tregs expressing phosphorylated NF-
kB in an unstimulated sample and an anti-CD3/28 stimulated
sample. Both stimulated and unstimulated samples were stained
with a monoclonal antibody against NF-kB p65 phosphorylation.
B) The average percentage of Tregs expressing NF-kB phosphor-
ylation in unstimulated and stimulated samples are depicted as
mean 6 SEM of six independent experiments. C) Inhibition of
phosphorylated NF-kB is shown for Tregs. TAC 10 ng/mL
inhibited NF-kB phosphorylation by 44.5% in Tregs (p,0.05;
mean 6 SEM of 6 independent experiments).
(TIF)
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